Gagelmann N, Bacigalupo A, Rambaldi A, et al. - The outcomes of haploidentical (HAPLO) stem cell transplantation with posttransplant cyclophosphamide therapy vs other transplant types in adults with hematologic cancers were determined. Researchers performed a meta-analysis of 30 studies including 22,974 patients. They identified that the use of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy resulted in increased all-cause mortality compared with matched related donors, similar all-cause mortality compared with matched unrelated donors, and reduced all-cause mortality compared with mismatched unrelated donors. Compared with matched unrelated donors, there appeared increased relapse in lymphoma and similar relapse in acute leukemia. Findings favor haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy as a preferred option to mismatched unrelated donors and highlight the necessity for prospective comparisons with matched donors.